gw420867x has been researched along with quinoxalines in 11 studies
| Studies (gw420867x) | Trials (gw420867x) | Recent Studies (post-2010) (gw420867x) | Studies (quinoxalines) | Trials (quinoxalines) | Recent Studies (post-2010) (quinoxalines) |
|---|---|---|---|---|---|
| 17 | 5 | 2 | 9,887 | 625 | 3,095 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (9.09) | 18.2507 |
| 2000's | 9 (81.82) | 29.6817 |
| 2010's | 1 (9.09) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Davies, LH; Dear, GJ; Ismail, IM; Mutch, PJ; Plumb, RS; Sweatman, BC | 2 |
| Duval, X | 1 |
| Balzarini, J; Burt, V; Carbonez, A; De Clercq, E; Kleim, JP | 1 |
| Cass, L; Prince, W; Segal, M; Thomas, S | 1 |
| Dear, GJ; Ismail, IM; Mutch, PJ | 1 |
| Cass, LM; Dallow, NS; Jones, AE; Moore, KH; Prince, WT; Sisson, JR | 1 |
| Boyce, M; Cass, LM; Dallow, N; Hardman, TC; Jones, A; Moore, KH; Prince, WT | 1 |
| Bye, A; Drusano, GL; Kleim, JP; Moore, KH; Prince, W | 1 |
| Chamberlain, PP; Chan, JH; Kleim, JP; Nichols, CE; Ren, J; Short, SA; Stammers, DK; Weaver, KL | 1 |
| Bickelhaupt, FM; Fonseca Guerra, C; Galembeck, E; Galembeck, SE | 1 |
3 trial(s) available for gw420867x and quinoxalines
| Article | Year |
|---|---|
The bioavailability of the novel nonnucleoside reverse transcriptase inhibitor GW420867X is unaffected by food in healthy male volunteers.
Topics: Adult; Area Under Curve; Biological Availability; Confidence Intervals; Cross-Over Studies; Dietary Fats; Food-Drug Interactions; Gastrointestinal Diseases; Half-Life; Headache; Humans; Least-Squares Analysis; Male; Metabolic Clearance Rate; Middle Aged; Quinoxalines; Reverse Transcriptase Inhibitors | 2001 |
Pharmacokinetics and tolerability of GW420867X, a nonnucleoside reverse transcriptase inhibitor, following single escalating doses in healthy male volunteers.
Topics: Adolescent; Adult; Analysis of Variance; Confidence Intervals; Double-Blind Method; HIV Infections; Humans; Male; Middle Aged; Quinoxalines; Reverse Transcriptase Inhibitors | 2001 |
Rational dose selection for a nonnucleoside reverse transcriptase inhibitor through use of population pharmacokinetic modeling and Monte Carlo simulation.
Topics: Double-Blind Method; Half-Life; HIV Infections; Humans; Microbial Sensitivity Tests; Models, Biological; Monte Carlo Method; Population; Protein Binding; Quinoxalines; Reverse Transcriptase Inhibitors | 2002 |
8 other study(ies) available for gw420867x and quinoxalines
| Article | Year |
|---|---|
Urinary metabolites of a novel quinoxaline non-nucleoside reverse transcriptase inhibitor in dog, cynomolgus monkey and mini-pig.
Topics: Animals; Chromatography, High Pressure Liquid; Dogs; Macaca fascicularis; Magnetic Resonance Spectroscopy; Male; Mass Spectrometry; Molecular Structure; Quinoxalines; Reverse Transcriptase Inhibitors; Species Specificity; Swine | 1999 |
[The 39th ICAAC (San Francisco) and the 7th European Conference on Clinical Aspects and Treatment of HIV-infection (Lisbon). HIV infection: antiretroviral agents in the development and trial stage].
Topics: Alkynes; Animals; Anti-HIV Agents; Antiviral Agents; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; Drug Therapy, Combination; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Oxazines; Quinoxalines; Reverse Transcriptase Inhibitors; Time Factors; Uracil; Viral Load | 2000 |
Long-term exposure of HIV type 1-infected cell cultures to combinations of the novel quinoxaline GW420867X with lamivudine, abacavir, and a variety of nonnucleoside reverse transcriptase inhibitors.
Topics: Alkynes; Anilides; Anti-HIV Agents; Benzoxazines; Cell Line; Cyclopropanes; Delavirdine; Dideoxynucleosides; Dose-Response Relationship, Drug; Drug Combinations; Drug Resistance, Microbial; Furans; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Microbial Sensitivity Tests; Mutation; Nevirapine; Oxazines; Quinoxalines; Reverse Transcriptase Inhibitors; Thioamides; Uracil | 2000 |
Urinary metabolites of a novel quinoxaline non-nucleoside reverse transcriptase inhibitor in rabbit, mouse and human: identification of fluorine NIH shift metabolites using NMR and tandem MS.
Topics: Animals; Chromatography, High Pressure Liquid; Humans; Magnetic Resonance Spectroscopy; Mass Spectrometry; Mice; Quinoxalines; Rabbits; Reverse Transcriptase Inhibitors | 2000 |
Brain and CSF entry of the novel non-nucleoside reverse transcriptase inhibitor, GW420867X.
Topics: Animals; Blood-Brain Barrier; Brain; Capillaries; Chemical Phenomena; Chemistry, Physical; Guinea Pigs; Mannitol; Quinoxalines; Reverse Transcriptase Inhibitors; Solubility | 2000 |
Formation of a defluorinated metabolite of a quinoxaline antiviral drug catalysed by human cytochrome P450 1A2.
Topics: Anti-HIV Agents; Antiviral Agents; Biotransformation; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP1A2; Half-Life; Humans; In Vitro Techniques; Isoenzymes; Magnetic Resonance Spectroscopy; Mass Spectrometry; Microsomes, Liver; Quinoxalines | 2001 |
Relationship of potency and resilience to drug resistant mutations for GW420867X revealed by crystal structures of inhibitor complexes for wild-type, Leu100Ile, Lys101Glu, and Tyr188Cys mutant HIV-1 reverse transcriptases.
Topics: Anti-HIV Agents; Binding Sites; Crystallography, X-Ray; Drug Resistance, Viral; HIV Reverse Transcriptase; HIV-1; Models, Molecular; Molecular Structure; Mutation; Protein Binding; Quinoxalines; Reverse Transcriptase Inhibitors | 2007 |
Effects of the protonation state in the interaction of an HIV-1 reverse transcriptase (RT) amino acid, Lys101, and a non nucleoside RT inhibitor, GW420867X.
Topics: Anti-HIV Agents; Binding Sites; Electrons; HIV Reverse Transcriptase; Hydrogen-Ion Concentration; Ligands; Lysine; Molecular Docking Simulation; Molecular Structure; Protein Binding; Protein Conformation; Quantum Theory; Quinoxalines; Reverse Transcriptase Inhibitors | 2014 |